HTLV-I causes adult T-cell leukemia and HTLV-I-associated myelopathy (HAM)' and has been associated with several other human diseases, including polymyositis, arthropathy, and cutaneous disorders.24 HTLV-I1 has been reported in patients with a rare T-cell variant of hairy cell leukemia' and has recently been associated with a neurologic disorder similar to HTLV-I-associated myel~pathy,~.' although neither association is firm. Both HTLV-I and HTLV-I1 can be transmitted parenterally, by sexual contact with an infected partner, and from mother to child, via breast feeding. ' The env gene of HTLV is expressed as a single precursor, gp61, that is processed into two smaller proteins gp21 and gp46. The larger protein gp46 is expressed on the surface of both virions and infected cells and is associated with gp21, which spans the cellular/viral membrane. The env proteins contain multiple immunogenic epitopes to which HTLVinfected individuals develop an antibody Recombinant proteins expressing the majority of HTLV-I gp21 are broadly immunoreactive with sera from HTLV-I-and HTLV-11-infected individual^?,'^"^ One of these recombinant proteins, p21E, which expresses amino acids 306 to 439 of the HTLV env gene,I4 has been incorporated into several commercially available assays and has greatly facilitated the detection of env specific antibodies in HTLV-Y 
reacted with BA21 . With virtually complete reactivity to sera from HTLV-infected individuals and no reactivity to sera from p2lE-reactive uninfected individuals, GD21-I will be useful in immunoassays for the detection of HTLV infection. 0 1995 by The American Society of Hematology.
11-infected individual^.'^"^ However, several reports have indicated that antibodies to the p21E recombinant protein are also found in sera from some uninfected individuals.'s2" These sera are negative for anti-HTLV-I antibodies by radioimmunoprecipitation assay (FUPA), and peripheral blood mononuclear cells (PBMCs) from these individuals are negative for the presence of HTLV-specific nucleic acid by polymerase chain reaction (PCR) analysis using HTLV-I-and HTLV-11-specific oligonucleotide primers and probes.'"'' It is not known whether the immunogenic regions of HTLV-I gp21 recognized by infected and uninfected individuals are the same or can be differentiated.
To further define the immunodominant epitopes within HTLV-I gp21, we isolated anti-gp21 antibodies by EpsteinBarr virus (EBV) activation of B-cell lines derived from an HTLV-I-infected individual suffering from HAM. The highly specific anti-gp21 antibodies obtained were used to screen a series of recombinant proteins expressing selected portions of HTLV-I gp21. Recombinant proteins found to be immunoreactive with either the anti-gp21 oligoclonal antibodies and/or HTLV antisera were purified, and the immunoreactivity of the purified proteins was determined with a panel of sera from HTLV-I-and HTLV-11-infected individuals. Evidence for the presence of two highly immunoreactive epitopes within the sequences of the p21E recornbinant protein is presented. The specificity of these two epitopes was then evaluated with a panel of sera derived from p21E-reactive but HTLV-negative individuals. One of the two epitopes, designated GD21-I, did not react with any of p21E reactive but HTLV-negative antisera and is thus highly HTLV specific.
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produced by inoculating New Zealand White rabbits with approximately 500 p g of purified glutathione-S-transferase produced by bacteria expressing nonrecombinant pGEX-1 plasmid."
This study also uses a panel of 17 sera that are reactive with the p21E protein from individuals with no other evidence for HTLV infection. The sera were identified in routine blood screening with HTLV-I EIA (Abbott Laboratories, Chicago, IL) and were found to have antibodies to the p21E recombinant protein (Cambridge Biotech, Rockville, MA, and/or Genelabs Diagnostics, Singapore Science Park, Singapore). Some of these sera also had gag protein reactivity. (The reactivity of these sera to viral gag antigens is presented in Table 2 below.) Reactivity of the p21E reactive sera to gp46 env protein was determined using a modified Western blot (HTLV Blot 2.3; Genelabs Diagnostics) that includes the recombinant proteins MTA-1 and K55 derived from the central portion of HTLV-I and HTLV-11 gp46, respectively." Additionally 10 of the 17 sera were tested for the presence of anti-env antibodies by RIPA as described.I8 Finally, 14 of the 17 sera were tested for the presence of HTLV nucleic acids by PCR using the primer pairs SK 110/111 and SK 43/44, which amplify both HTLV-I and HTLV-I1 nucleic acids, and the primer pairs SK54/55 and SK 58/59, which are specific for HTLV-I and HTLV-I1 nucleic acids, re~pectively.2~ PCR reaction and subsequent hybridizations with HTLV-I-and HTLV-II-specific probes were performed as d e s~r i b e d . '~~~~ PCR analysis of the other three p21E reactive sera used was prohibited by the insufficient volume of the sample.
Production of gp21-speci)ic antibodies. Peripheral B cells were isolated from an HTLV-I-infected individual who was suffering from HAM. T cells were removed by rosetting with sheep red blood cells and the resulting enriched preparation of B cells was seeded at IO4 cells/well in 96-well microtiter plates (Coming Costar Corp, Cambridge, MA) and activated with EBV as de~cribed.'~.'~ Cultures exhibiting specific anti-HTLV-I IgG activity were identified using an indirect immunofluorescence assay in which supernatants from actively dividing cultures were incubated with the HTLV-I-infected cell line Iv~T-~.'~ Two of the activated B-cell cultures secreted antibodies to gp21 by Western blot analysis (HTLVblot 2.3; Genelabs Diagnostics). Tissue culture supernants from these two cell lines, 5G4 and 6E9, were used in this study. Additional supernatants from these activated B cells were produced and used in subsequent studies.
Construction of recornbinant clones. Oligonucleotide primers whose DNA sequences were based on the sequence reported for the ATK strain of HTLV-I" were designed and synthesized on an automated synthesizer (Applied Biosystems, Foster City, CA), following the manufacturer's instructions. All of the primers contained either a BarnHI, NCO I, and/or EcoRI site located at their 5' ends to facilitate cloning of the amplified DNA fragments as an in-frame insertion into a modified version of the vector pGEX-2" (obtained from Pharmacia, Piscataway, NJ) that contains an NCO I site just 5' to the existing BamHI and EcoRI sites. The locations of the 5' and 3' ends of the HTLV DNA sequences of the various HTLV-I gp21 recombinant antigens were selected on the basis of the hydrophilicity profiles of HTLV-I gp21 as determined by the program Antigen" within the software package PC-Gene (Intelligenetics, Mountain View, CA).
PCR was performed according to the manufacturer's instructions (Perkin-Elmer/Cetus, Norwalk, CT), and all PCR reactions contained 2 ng of the HTLV-I clone sp65 MT-2 (generously provided by Dr F. Wong-Staal, Department of Medicine, University of California, San Diego, CA) as template and 1.0 pmol/L of the appropriate oligonucleotide primers. PCR amplification was performed for 25 cycles of template denaturation (1 minute at 94"C), primer annealing (2 minutes at 50"C), and primer extension (2 minutes at 72°C). Amplified DNA fragments were purified, digested for 2 hours with the appropriate restriction enzymes, and then ligated into similarly digested modified pGEX-2. The recombinant plasmids were then used to transform Escherichia coli strain JMlOl (Epicurean Coli; Stratagene, La Jolla, CA). Plasmid-containing bacteria were screened for protein production by Western blot analysis of crude lysates prepared from 2-mL cultures of the transformed E coli as de~cribed.'~ The resulting Westem blots were then incubated overnight at room temperature with HTLV-infected or control antisera diluted 11100 or with tissue culture supernatants from the cell lines 6E9 and 5G4 diluted 112 in BLOTTO (10 mmoVL Tris-HC1, pH 7.4, 5% nonfat dry milk, 2.5% normal goat sera, and 0.5% Tween-20). The Western blots were washed, and bound human IgG was detected as described p r e v i o~s l y '~~~'
PuriJication of recombinant proteins. Purification of recombinant fusion protein was performed essentially as described.".*' Briefly, a 10-mL overnight culture of bacteria containing the recombinant plasmid of interest was diluted 11100 into flasks containing 500 mL of NZYDT mediaz9 with 100 pg/mL ampicillin. Expression of fusion protein was induced by the addition of isopropyl-P-D-thiogalactopyranoside (IPTG; final concentration, 0.2 mmol/L) to logphase cultures. The cultures were grown for an additional 3 to 4 hours at 37"C, at which point the bacteria were pelleted by centrifugation at 5,000g for 10 minutes. The cells were resuspended in 20 mL of cold phosphate-buffered saline (PBS) and were lysed by several cycles of freezing and thawing. After lysis, proteins were solubilized by the addition of Triton X-100 (Sigma, St Louis, MO) to 1.0%, DNAse I to 1 pg/mL, and aprotinin to 1.0%. After incubation for 5 minutes at 25T, insoluble cellular debris was pelleted by centrifugation 2 times at 10,OOOg for 10 minutes, and the supernatants were reserved. Aliquots from both the pellet and supernatant fraction were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)M to determine if the recombinant proteins were solubilized by the above procedure.
Although the majority of GD21-I was insoluble, sufficient quantities for further studies of both the GD21-I and BA21 recombinant proteins were present in the soluble fraction. The supernatants were then passed through a column containing 0.8 mL of glutathione agarose (Phmacia, Piscataway, NJ) that was pretreated as recommended by the manufacturer. The column was washed with 10 mL of MTBS (150 mmol/L NaCI, 16 mmoVL Na,HPO,, 4 mmoVL Na&P04; pH 7.3)" plus 1% Triton and 1% Aprotinin, followed by a 5-mL wash with MTBS alone. Bound proteins were eluted with buffer containing 5 mmol/L glutathione in 50 mmoVL Tris, pH 8.0, and 10 l-mL fractions were collected. The location of the peak of eluted protein was determined by measuring the absorbance at 280 nm of the fractions and by SDS-PAGE analysis of aliquots of the fractions. For both of the recombinant proteins a 1 L culture resulted in the purification of 1 to 2 mg of fusion protein at a purity of approximately 70%. Fractions containing significant amounts of protein were pooled, and aliquots of this pool were frozen at -70°C for subsequent analysis.
Serologic analysis of purified recombinant peptides. Aliquots of the purified GD21-I and BA21 proteins were separated under reducing conditions on a 11.5% polyacrylamide gel. The resolved proteins were electroblotted onto a nitrocellulose membrane, blocked with BLO'lTO, air-dried, and cut into 2-mm wide strips. The strips were rehydrated in 'ITBS buffer (150 mmoVL NaCI, 20 mmol/L Tris, pH 7.5, 0.2% Tween-20) and incubated overnight with sera diluted 150 in BLOTTO. The strips were washed three times with TTBS and incubated for 1 hour with goat antihuman IgG conjugated to alkaline phosphatase (Bio-Rad, Hercules, CA). After washing four times with TBS, bound antibody was detected by incubating the strips in a substrate solution containing NBT and BCIP in 100 mmoVL Tris-HCI buffer, pH 9.5, 50 mmol/L MgC12. Color development was continued until a uniform background developed on the strip and was halted by rinsing the strips two times with deionized water. 
RESULTS
Peripheral B cells from an HTLV-infected individual with HAM were isolated and activated by infection with EBV. Two cell lines, SG4 and 6E9, were isolated that reacted specifically with Western blotted p21E recombinant protein (Fig 1) . No immunoreactivity to any other HTLV protein was detected. Although the two cell lines were originally derived from the EBV activation of IO4 B cells, they produced antibodies that were highly specific for reactivity to the p2 1 E region of HTLV-I gp2 I .
The p21E-specific antibodies produced by the 6E9 and 5G4 cell lines were then used to determine the immunogenic sequence(s) within gp21. Eight oligonucleotide primers (Table l ) were synthesized and used to amplify seven DNA rgp46-I + p24 + p21 E + fragments that expressed selected portions of HTLV-I gp21 (Fig 2A) . The start and stopping points of the various recombinant clones were designed to express the four major peaks of hydrophilicity present in the p21E region of gp21 either alone or in combination (Fig 2A) . All of the inserts were successfully expressed as recombinant fusion proteins and four of the recombinant clones 2A3B. UG21, GD2I-I. and BA21 were also DNA sequenced by the dideoxy termination procedure." The sequence of the DNA inserts obtained confirmed that the four recombinant proteins were expressing the desired regions of HTLV-I gp21.
The immunogenicity of supernatants from the SG4 and 6E9 cell lines was assessed by Western blot analysis of whole cell lysates of bacteria expressing six of the gp21 recombinant proteins (Fig 2) . The expression of all six of the recombinant proteins tested was verified by Coomassie Blue protein staining (data not shown). None of the four constructs expressing all or part of amino acids 299 to 365 of the HTLV env proteins reacted with tissue culture supernatants from either of the anti-p21E-activated B cells tested (Fig 2B) . In addition, neither of the two p21E antibodies reacted with the recombinant protein BA21, which expressed amino acids 397 to 430 of the HTLV-I env protein. However, tissue culture supernatants from both the 5G4 and 6E9 cell 
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These data suggested that an immunodominant epitope was located between amino acids 365 and 397 of the HTLV-I e w gene in the sequences of the 2A3B recombinant protein that were not shared with the UG21 or RA21 recombinant proteins. Therefore. a recombinant protein, GD21-I, that expressed amino acids 361 to 404 of the HTLV-I e m ' gene was constructed and the immunoreactivity of GD21-I with tissue culture supernatants from the 6E9 and SG4 cell lines was determined (Fig 2C) . As expected. both anti-p21E antibodies reacted with the smaller GD21-I recombinant protein.
To confirm that the results obtained with the anti-p21E antibodies would also be true for polyclonal sera, the reactivity of the recombinant proteins against sera from S HTLV-I-and 3 HTLV-11-infected individuals was also determined. Whole cell lysates from bacteria expressing several of the recombinant proteins were fractionated by SDS-PAGE and Western blotted. Representative Western blots obtained are presented in Fig 3. All HTLV-I-and HTLV-11-infected sera tested reacted with the recombinant protein GD21-I. Serum from 1 HTLV-I-and 1 HTLV-11-infected individual tested also reacted with the RA21 recombinant protein. This To determine the overall reactivity of GD21-I and BA21 to HTLV-infected sera. the recombinant proteins were purified via glutathione agarose affinity chromatography and Western blots were prepared as described. The resulting blots were then cut into 2-mm strips and incubated with panels of sera from HTLV-I/II-infected individuals. p2 1 E-reactive but HTLV-negative individuals. and HTLV-negative blood donors. Representative Western blots obtained are presented in Fig 4. The immunoreactive band visible in several lanes migrating below GD2I-I was not reactive with either the 6E9 and SG4 supernatants or antisera directed against the sj26 portion of the GD21-I recombinant protein and represents a contaminant of the purification. The very faint reactivity to full-length CD2 1 -I observed in three of the control sera (Fig 4) was not reproducible in two additional experiments, and the sera were determined to be GD2 1 -I negative.
The results from the entire panel of sera are presented in Table 2 . We tested sera from 54 individuals who were positive for infection with HTLV-I or HTLV-I1 by both serologic criteria and whose sera were positive when tested by PCR with HTLV-specific primers and probes. Overall, sera from 26 of 26 HTLV-I-infected individuals and 28 of 28 HTLV-11-infected individuals reacted strongly with the recombinant protein GD21-I. The BA21 protein was reactive with 14 of 26 HTLV-I-infected and 19 of 28 HTLV-11-infected individuals, although in some cases the reactivity observed was relatively weak (Fig 4) .
To assess the specificity of the epitopes, the GD2I-I and BA21 recombinant proteins were tested against a panel of 24 HTLV-negative sera. This panel included sera from 17 HTLV indeterminate individuals, including 8 that were reactive with p21E and 9 that reacted with p21E and an HTLV gag protein (Table 2) . PCR amplification of 14 of the 17 HTLV indeterminate sera with HTLV-specific primers and probes was negative. Of these sera, only the 3 that are reactive to both p21E and p24 might be classified as HTLV infected on the basis of p24 plus env reactivity; however, these sera were neither reactive with the HTLV-specific gp46 proteins MTAl and K55 nor positive for HTLV infection when tested by PCR. None of the 24 control sera, including the 17 p21E-reactive HTLV-negative sera, reacted with GD21-I-recombinant protein. In contrast, a total of 17 sera, including 16 of the p21E-reactive HTLV indeterminate sera reacted with the BA21 protein ( Table 2) . Thus. the GD2I-I recombinant protein expresses an epitope that is both highly sensitive and highly specific for sera from individuals who can be shown to be HTLV infected by both serologic and PCR-based criteria.
DISCUSSION
Immunogenic epitopes within the surface glycoprotein gp46 and the transmembrane glycoprotein gp21 have been shown to elicit strong antibody responses from HTLV-Iand HTLV-11-infected individuals.x"3 Several reports have confirmed that recombinant proteins that express the majority of the sequence of HTLV-I gp21 are broadly reactive with sera from HTLV-I-and HTLV-11-infected individuals.""' In addition, work by Manns et al-" has indicated that antibodies to the gp21, detected using the recombinant protein p21E," are generally among the first to appear during seroconversion to HTLV-I. The broad reactivity of gp21 recombinant proteins coupled with the difficulty of establishing reactivity to native Western blotted env has led to the incorporation of the recombinant protein p21E into HTLV screening and confirmatory assays and has reduced the need to perform more cumbersome confirmatory tests, such as RIPA.'7.'X However. it has also been established that some individuals who are not HTLV-I or HTLV-I1 infected For personal use only. on November 11, 2017. by guest www.bloodjournal.org From On 0/2 1 * PCR analysis of HTLV-infected and indeterminate sera was performed as described in the Materials and Methods. Unless otherwise indicated, the total number of samples tested is indicated in the column labeled N. t None of the HTLV indeterminate sera were reactive with the HTLV-I-and HTLV-ll-specific gp46 recombinant proteins MTA-1 or K55. Additionally, 10 of the p21E-reactive sera, including all that were coreactive with p24, were negative for evidence for HTLV infection when tested by RIPA.
also possess an antibody response to the p21E protein.'8s19 In one study, antibodies to p21E were observed in 0.6% of uninfected blood donors." Subsequent RIPA testing of these p21E-reactive sera confirmed that they do not react with native gp61 env protein." PCR testing of HTLV indeterminate p21E-reactive individuals with HTLV-specific primers and probes has also indicated that these individuals are HTLV negative.'8*20 The cross-reactivity of the p21E recombinant protein with sera from uninfected individuals limits its utility in the diagnosis of HTLV infection."
It is therefore important to further define the immunogenic regions recognized by HTLV-I-and HTLV-11-infected sera within the 134 amino acid sequence of the p21E protein. To accomplish this, we used highly specific preparations of antip21E antibodies from EBV-activated B cells of an HTLV-I-infected individual and determined the reactivity of these antibodies towards a series of recombinant proteins that expressed selected portions of gp21. This approach is very analogous to that used previously to isolate the HTLV-Ispecific epitope contained within the gp46 recombinant protein MTA-l.".*'
Antibodies produced by two anti-p21E EBV-activated B-cell lines were specifically reactive with a recombinant protein, GD21-I, that expressed amino acids 361 to 404 of the HTLV-I env gene. Analysis of a panel of 54 sera from HTLV-I-and HTLV-II-infected individuals indicated that 100% of the sera reacted with the GD21-I protein. A second highly immunoreactive domain, recognized by approximately 60% of HTLV antisera tested, was contained within the recombinant protein BA21 that expressed amino acids 397 to 430 of the HTLV-I env gene. Only minor amounts of reactivity to recombinant proteins expressing amino acids 299 to 365 of the HTLV env gene were observed after limited testing. Thus, we show that two immunogenic regions are contained within the sequences of p21E.
Our results contrast with those of several previous studies that failed to delineate an immunodominant epitope within HTLV-I g~2 1 .~~"~'~ These studies all used synthetic peptides encoding sequences derived from selected regions of HTLV-I gp21. In a very thorough analysis by Horal et al . " the entire coding sequence of the HTLV-I env gene was synthesized as a series of overlapping synthetic peptides of approximately 22 amino acids in length. The results obtained indicated that there were multiple immunogenic epitopes present within the sequences of p21E; however, none of the peptides was universally reactive with HTLV-I-and HTLV-11-infected sera. We believe that the use of human monoclonal antibodies permits a more definitive analysis of epit~pes.".'~ In this effort the oligoclonal human antibody preparations possessed highly specific antibodies to gp21, which allowed for the isolation of GD21-I and permitted a more definitive characterization of the immondominant epitope of HTLV This study is also the first to delineate the location of the epitope Thus, the immunodominant epitope recognized by truly HTLV-infected individuals and the epitope recognized by p21E-reactive but HTLV PCR-negative individuals are distinct. The lack of immunoreactivity towards this sequence among HTLV indeterminate individuals indicates that the GD21-I protein holds great promise as being the basis of improved HTLV confirmatory and screening assays possessing an increased specificity over currently used tests.
More specific serologic assays for HTLV infection would greatly benefit accurate testing and counseling of volunteer blood donors as well as epidemiologic studies of HTLV-I and HTLV-II infection. gP2 1.
